Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Clinical trial NCT03865082 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03865082
- Sponsor
- Idera Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-29
- Primary completion
- 2022-03-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.